Buscar
Predictive Oncology Inc
POAIAñadir a la lista de seguimiento
5.950USD
0.0000.00%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
75.12MCap. mercado
PérdidaP/E TTM
Más Datos de Predictive Oncology Inc Compañía
Predictive Oncology Inc. is engaged in using artificial intelligence (AI) and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The Company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy when a tumor sample responds to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Through AI, it uses its proprietary biobank of 150,000+ cancer tumor samples, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of drug development. The Company offers a suite of solutions for oncology drug development from early discovery to clinical trials.
Información de Predictive Oncology Inc
Símbolo de cotizaciónPOAI
Nombre de la empresaPredictive Oncology Inc
Fecha de salida a bolsaDec 18, 2009
Director ejecutivoVennare (Raymond F)
Número de empleados23
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 18
Dirección91 43Rd Street
CiudadPITTSBURGH
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal15201
Teléfono14124321500
Sitio Webhttps://predictive-oncology.com/
Símbolo de cotizaciónPOAI
Fecha de salida a bolsaDec 18, 2009
Director ejecutivoVennare (Raymond F)
Ejecutivos de Predictive Oncology Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Raymond F. Vennare
Mr. Raymond F. Vennare
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
19.68K
+0.01%
Mr. Joshua Blacher
Mr. Joshua Blacher
Interim Chief Financial Officer
Interim Chief Financial Officer
15.86K
+59.21%
Dr. Daniel E. (Dan) Handley, Ph.D.
Dr. Daniel E. (Dan) Handley, Ph.D.
Independent Director
Independent Director
13.07K
+43.32%
Dr. Veena Rao, Ph.D.
Dr. Veena Rao, Ph.D.
Independent Director
Independent Director
9.12K
+46.03%
Mr. Chuck (Charles) Nuzum, Sr.
Mr. Chuck (Charles) Nuzum, Sr.
Lead Independent Director
Lead Independent Director
--
--
Mr. Gregory S. St. Clair, Sr.
Mr. Gregory S. St. Clair, Sr.
Independent Director
Independent Director
--
--
Dr. Matthew J. Hawryluk, Ph.D.
Dr. Matthew J. Hawryluk, Ph.D.
Independent Director
Independent Director
--
--
Mr. Shawn P. Matthews
Mr. Shawn P. Matthews
Director
Director
--
--
Mr. Thomas McLaughlin
Mr. Thomas McLaughlin
Chief Investment Officer
Chief Investment Officer
--
--
Ms. Sara Turken
Ms. Sara Turken
General Counsel
General Counsel
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Raymond F. Vennare
Mr. Raymond F. Vennare
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
19.68K
+0.01%
Mr. Joshua Blacher
Mr. Joshua Blacher
Interim Chief Financial Officer
Interim Chief Financial Officer
15.86K
+59.21%
Dr. Daniel E. (Dan) Handley, Ph.D.
Dr. Daniel E. (Dan) Handley, Ph.D.
Independent Director
Independent Director
13.07K
+43.32%
Dr. Veena Rao, Ph.D.
Dr. Veena Rao, Ph.D.
Independent Director
Independent Director
9.12K
+46.03%
Mr. Chuck (Charles) Nuzum, Sr.
Mr. Chuck (Charles) Nuzum, Sr.
Lead Independent Director
Lead Independent Director
--
--
Mr. Gregory S. St. Clair, Sr.
Mr. Gregory S. St. Clair, Sr.
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Predictive Oncology Inc?
Los cinco principales accionistas de Predictive Oncology Inc son: Mr. Raymond F. Vennare
¿Cuántas instituciones poseen acciones de Predictive Oncology Inc (POAI)?
A fecha de 2026Q1, 40 instituciones poseen acciones de Predictive Oncology Inc, con un valor de mercado combinado de aproximadamente 185.91K, lo que representa el 3.36% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 138692.00.